(Q24240500)

7

0 references

Christine Rummel-Kluge

2

0 references

Katja Komossa

1

0 references

author name string

Heike Hunger

3

0 references

Franziska Schmid

4

0 references

Sandra Schwarz

Cochrane Database of Systematic Reviews

5

0 references

publication date

20 January 2010

0 references

published in

0 references

cites work

Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Zotepine for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Olanzapine for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Aripiprazole for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Imputing missing standard deviations in meta-analyses can provide accurate results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

What does the PANSS mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Clinical implications of Brief Psychiatric Rating Scale scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Schizophrenia and employment - a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

Suicide in schizophrenics, manics, depressives, and surgical controls. A comparison with general population suicide mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006628.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/14651858.CD006628.PUB2

0 references

Fatcat ID

release_63glg2hcl5frpbntaemmypdr6q

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/63glg2hcl5frpbntaemmypdr6q